The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.
about
Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted AgentsKnow the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemiaThe novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.MCPIP1 contributes to the toxicity of proteasome inhibitor MG-132 in HeLa cells by the inhibition of NF-κBTumor necrosis factor-α sensitizes breast cancer cells to natural products with proteasome-inhibitory activity leading to apoptosisCarfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses.Targeted therapy in chronic lymphocytic leukemia: past, present, and future.The isopeptidase inhibitor 2cPE triggers proteotoxic stress and ATM activation in chronic lymphocytic leukemia cells.Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.Apoptosis inducers in chronic lymphocytic leukemia.Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study.PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance.Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia.Proteasome inhibition blocks necroptosis by attenuating death complex aggregation.Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response
P2860
Q26764833-42395957-430E-4788-9DA8-03B2AFFE8756Q26781895-477DB210-3874-4A6B-A7B8-14022E4F1287Q28392681-EE0DE6AD-2AA7-4FEF-8F0B-6C58B995FFE5Q33420278-45AF2CC3-7A92-48EA-9731-94D267AD086FQ34038263-3ABA2D6E-B2FB-4753-9F13-F63C9A508DDAQ34566295-9B88F188-1F2B-4D02-9E38-C075780345B0Q37427124-2E50B696-1F74-45A9-87DF-B898B26E64C5Q37430243-E77BC9B7-52F6-482F-90E4-DFCE252FF399Q37564440-27FD2DE3-BB4F-41F9-8AB1-E7E254A48173Q37689041-ED62AAB2-92EC-41F3-9BFA-5FDBF0CC0BB5Q38124119-44AC14AB-E1F6-4F13-98FA-34DBFE3C55DAQ38187815-75273FDC-B388-49FB-A099-4F1506334EA4Q38882194-9A34B947-C520-4781-A34B-7C16FA3A3861Q39036088-45BF9B63-01A1-4CDF-8774-3865AFC315D2Q43096794-F457BA89-C12C-48D9-823B-52FE3A1EDBA6Q52370139-0CF582AA-1512-434D-A545-4FB61150CC9EQ58779410-30C2BBE6-66C2-49E1-A7F5-88AE58D144F9
P2860
The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
The proteasome inhibitor carfi ...... ic lymphocytic leukemia cells.
@ast
The proteasome inhibitor carfi ...... ic lymphocytic leukemia cells.
@en
type
label
The proteasome inhibitor carfi ...... ic lymphocytic leukemia cells.
@ast
The proteasome inhibitor carfi ...... ic lymphocytic leukemia cells.
@en
prefLabel
The proteasome inhibitor carfi ...... ic lymphocytic leukemia cells.
@ast
The proteasome inhibitor carfi ...... ic lymphocytic leukemia cells.
@en
P2093
P2860
P1476
The proteasome inhibitor carfi ...... ic lymphocytic leukemia cells.
@en
P2093
Amy Lehman
David Jarjoura
David M Lucas
Ellen J Sass
Erin Hertlein
Jennifer A Woyach
Melanie E Davis
Rosa Lapalombella
Sneha V Gupta
Timothy L Chen
P2860
P304
P356
10.1158/1078-0432.CCR-12-2754
P407
P50
P577
2013-03-20T00:00:00Z